AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aktis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$15.11+0.05 (+0.33%)
Close on Oct 19, 2026
- Market cap
- $835.58M
- P/E (TTM)
- –
- Dividend yield
- –
Aktis Oncology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Aktis Oncology | Industry median |
|---|---|---|
| Market Cap | $840.41M | $166.30M |
| Enterprise Value | $323.11M | $88.19M |
| PB Ratio | 1.73 | 2.03 |
| P/TBV Ratio | 1.73 | 2.29 |
Balance sheet
| Measure | Aktis Oncology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $517.30M | $61.43M |
| Net Cash (Debt) | $517.30M | $15.35M |
| Net Cash Per Share | $9.30 | $0.66 |
| Equity (Book Value) | $484.84M | $49.09M |
| Book Value Per Share | $8.72 | $1.37 |
| Tangible Book Value | $484.84M | $23.52M |
| Working Capital | $492.41M | $76.81M |
Financial position
| Measure | Aktis Oncology | Industry median |
|---|---|---|
| Current Ratio | 16.33 | 3.34 |
| Quick Ratio | 16.10 | 2.44 |
Efficiency
| Measure | Aktis Oncology | Industry median |
|---|---|---|
| Employee Count | 79 | 74 |
Shares
| Measure | Aktis Oncology | Industry median |
|---|---|---|
| Shares Outstanding | 55,619,500 | 58,127,000 |
| Shares Change (QoQ) | 0.08% | 0.54% |
| Float | 28,027,800 | 49,136,700 |
| Shares Held by Insiders | 49.6% | 11.6% |
| Shares Held by Institutions | 61.4% | 59.4% |
Scores
| Measure | Aktis Oncology | Industry median |
|---|---|---|
| Altman Z-Score | 7.49 | -0.22 |
Calculated by StockData from Aktis Oncology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.